Literature DB >> 18589404

Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition.

Stefan J Borgwardt1, Paul Allen, Sagnik Bhattacharyya, Paolo Fusar-Poli, Jose A Crippa, Marc L Seal, Valter Fraccaro, Zerrin Atakan, Rocio Martin-Santos, Colin O'Carroll, Katya Rubia, Philip K McGuire.   

Abstract

BACKGROUND: This study examined the effect of Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on brain activation during a motor inhibition task.
METHODS: Functional magnetic resonance imaging and behavioural measures were recorded while 15 healthy volunteers performed a Go/No-Go task following administration of either THC or CBD or placebo in a double-blind, pseudo-randomized, placebo-controlled repeated measures within-subject design.
RESULTS: Relative to placebo, THC attenuated activation in the right inferior frontal and the anterior cingulate gyrus. In contrast, CBD deactivated the left temporal cortex and insula. These effects were not related to changes in anxiety, intoxication, sedation, and psychotic symptoms.
CONCLUSIONS: These data suggest that THC attenuates the engagement of brain regions that mediate response inhibition. CBD modulated function in regions not usually implicated in response inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18589404     DOI: 10.1016/j.biopsych.2008.05.011

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  78 in total

Review 1.  Pitfalls in FMRI.

Authors:  Sven Haller; Andreas J Bartsch
Journal:  Eur Radiol       Date:  2009-06-06       Impact factor: 5.315

2.  Cannabis, a complex plant: different compounds and different effects on individuals.

Authors:  Zerrin Atakan
Journal:  Ther Adv Psychopharmacol       Date:  2012-12

Review 3.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

Review 4.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

Review 5.  The endocannabinoid system as a target for modelling psychosis.

Authors:  Dagmar Koethe; Carolin Hoyer; F Markus Leweke
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

Review 6.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

7.  THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia.

Authors:  David D Aguilar; Andrea Giuffrida; Daniel J Lodge
Journal:  J Psychopharmacol       Date:  2015-10-28       Impact factor: 4.153

Review 8.  Cannabinoids in experimental stroke: a systematic review and meta-analysis.

Authors:  Timothy J England; William H Hind; Nadiah A Rasid; Saoirse E O'Sullivan
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

9.  Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.

Authors:  David S Jacobs; Stephen J Kohut; Shan Jiang; Spyros P Nikas; Alexandros Makriyannis; Jack Bergman
Journal:  Exp Clin Psychopharmacol       Date:  2016-08-15       Impact factor: 3.157

10.  Should burden of disease estimates include cannabis use as a risk factor for psychosis?

Authors:  Louisa Degenhardt; Wayne D Hall; Michael Lynskey; John McGrath; Jennifer McLaren; Bianca Calabria; Harvey Whiteford; Theo Vos
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.